



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-057)

#11  
Amend. B  
PATENT  
2/24/03

TECH CENTER 1600:2900

RECEIVED

FEB 14 2003

In the Application of:

Chevalier

Serial No.: 09/744,659

Filing Date: April 18, 2001

For: Trimer of HIV env  
Gene Expression Product

Examiner: U. Winkler

Group Art Unit: 1648

Confirmation No.: 3396

**RESPONSE TO THE OFFICE ACTION MAILED NOVEMBER 6, 2002**

Box Non-Fee Amendment  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please consider the following amendments and remarks in response to the Office Action mailed November 6, 2002.

**AMENDMENTS**

**In the specification:**

*Please add the following as the first line of the specification:*

B<sup>1</sup> This application is a 35 U.S.C. § 371 filing of international application PCT/FR99/01871, file July 29, 1999.

*Please add the following as the abstract of the invention:*

**ABSTRACT OF THE INVENTION**

B<sup>2</sup> contd. The invention concerns a purified recombinant glycoprotein having the following properties: a) an adherence capacity to CD4; b) an affinity with a anti-gp120 antibody capable of neutralizing in vitro HIV cell infection; c) an affinity with an anti-gp41 antibody; d) a trimeric form free from inter-chain disulphide bonds. The invention also concerns a vaccine comprising said purified glycoprotein and an adjuvant. The invention further concerns a method for obtaining said glycoprotein, which consists in expressing, by means of genetic recombining techniques, a glycoprotein corresponding to the properties a), b) and c)

**CERTIFICATE OF MAILING (37 C.F.R. 1.8a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, Washington D.C. 20231, on February 6, 2003.

Date: February 6, 2003

Michael S. Greenfield